Edwin Rock News Today

Operator: Good morning, and thank you for joining the GlycoMimetics Q4 and Full Year 2023 Earnings Call. At this time, all participants are in a listen-only mode.

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the 65th American Society of Hematology (ASH) Annual Meeting will feature two presentations o...

GlycoMimetics, Inc. , a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the 65th American...

GlycoMimetics, Inc. (NASDAQ:GLYC – Get Free Report) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $1.36 and traded as high as $1.53. GlycoMimetics shares last traded at $1.53, with a volume of 79,729 shares. Analyst Ratings Changes Several research analysts recently weighed in […]

Operator: Good morning, and thank you for joining the GlycoMimetics Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode.

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

By Ben Glickman Shares of GlycoMimetics rose Tuesday after its chief medical officer bought over $90,000 worth of stock. The stock was up 12% to $1.44 in...

Operator: Good morning, and thank you for joining the GlycoMimetics, Q2 2023 Earnings Call. At this time all participants are in listen-only mode.

Operator: Good morning. And thank you for joining the GlycoMimetics Fourth Quarter and Full Year 2022 Earnings Call. At this time, all participants are in a listen only mode.